Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Telmisartan/Amlodipine low dose (Drug); Telmisartan/Amlodipine high dose (Drug); Japanese meal (Other)
Phase: Phase 1
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
Study to investigate the relative bioavailability and pharmacokinetics of the fixed-dose
combination tablets (telmisartan 40 mg/amlodipine 5 mg and telmisartan 80 mg/amlodipine 5
mg) in the fed condition compared with those of the same fixed-dose combination in the
fasting condition in healthy Japanese male volunteers.
Clinical Details
Official title: Influence of Food on the Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination and of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination in Healthy Japanese Male Volunteers (a Phase I, Open-label, Randomised, Single-dose, Two-way Crossover Trial)
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)Maximum measured concentration of the analyte in plasma (Cmax)
Secondary outcome: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)Time from dosing to the maximum concentration of the analyte in plasma (tmax) Terminal rate constant of the analyte in plasma (λz) Terminal half-life of the analyte in plasma (t1/2) Mean residence time of the analyte in the body after po administration (MRTpo) Number of subjects with adverse events
Eligibility
Minimum age: 20 Years.
Maximum age: 35 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
1. Healthy male volunteers without any clinically significant findings and complications
on the basis of a complete medical history, including the physical examination, vital
signs (blood pressure, pulse rate, body temperature), 12-lead electrocardiograms
(ECGs), clinical laboratory tests
2. Age: ≥20 and Age ≤35 years
3. Body weight: ≥50 kg
4. Body mass index (BMI): ≥18. 0 and ≤25. 0 kg/m2
5. Signed and dated written informed consent prior to admission to the trial in
accordance with the Good Clinical Practice (GCP) and the local legislation
Exclusion Criteria:
1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
immunological, or hormonal disorders
2. Diseases of the central nervous system (such as epilepsy) or psychiatric or
neurological disorders
3. Chronic or relevant acute infections
4. Any clinical relevant findings in laboratory test results deviating from normal
5. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus
(HCV) antibodies, a syphilitic test, or an human immunodeficiency virus (HIV) test
6. History of surgery of the gastrointestinal tract (except appendectomy)
7. History of relevant orthostatic hypotension, fainting spells, or blackouts
8. Known hypersensitivity to any component of the formulation (telmisartan and
amlodipine), to any other angiotensin II receptor blockers, or to any other
dihydropyridine compound
9. Intake of drugs with a long half-life (≥24 hours) within at least 1 month or less
than 10 half-lives of the respective drug before drug administration
10. Intake of drugs which might reasonably influence the results of the trial on the
basis of the knowledge at the time of protocol preparation within 7 days before drug
administration
11. Participation in another trial with an investigational drug within 4 months or 6
half-lives of the investigational products before drug administration
12. Smoker (≥20 cigarettes/day)
13. Alcohol abuse (60 g or more ethanol/day: e. g., 3 middle-sized bottles of beer, 3 gous
[equivalent to 540 mL] of sake)
14. Drug abuse
15. Blood donation (more than 100 mL within 4 weeks before drug administration)
16. Excessive physical activities (within 1 week before drug administration)
17. Intake of alcohol within 2 days before drug administration
18. Inability to comply with dietary regimen of the study centre
19. Inability to refrain from smoking during trial days
20. Subjects judged to be inappropriate by the investigator or a sub-investigator
Locations and Contacts
Additional Information
Starting date: December 2008
Last updated: October 9, 2014
|